Potential supervisors and their fields of research are featured below.
Professor Louisa Degenhardt: email@example.com
Epidemiology of illicit drug use (especially cannabis, amphetamines, cocaine and heroin); mortality among people who use drugs; drug use among young people; crime among opioid dependent people; injecting drug use; evidence for interventions to reduce harm among people who use drugs, including opioid agonist treatment; pharmaceutical opioid use, including by people who are living with chronic pain.
Associate Professor Rebecca McKetin: firstname.lastname@example.org
Stimulant use; methamphetamine use and harms; methamphetamine psychosis; epidemiology; in-direct prevalence estimation; sentinel surveys of substance use; cohort studies; service coverage and barriers to care.
Associate Professor Amy Peacock: email@example.com
Trends in illicit drug use, harms, and market features; uptake and evaluation of strategies to reduce risk of drug-related harm (e.g., drug checking, drug alerts); alcohol consumption, risk-taking and harm, particularly among young people; and use of pharmaceutical opioids and strategies to reduce extra-medical use and harm. Projects draw on cross-sectional surveys, longitudinal surveys, administrative (including linked) health data (e.g., mortality, hospitalisations), and online data (e.g., darknet marketplace listings).
Dr Natasa Gisev: firstname.lastname@example.org
Pharmaceutical opioid use and related harms; maximising treatment outcomes for people with opioid dependence, including those with co-morbid mental health disorders; quality use of opioids and psychotropic medicines, including evidence-based prescribing. Projects incorporate pharmacoepidemiological methods and the use of population-level linked administrative health data.
Dr Ryan Courtney: email@example.com
Smoking cessation; tobacco smoking in low socio-economic status (SES) and disadvantaged populations; socio-economic inequalities and health behaviours and outcomes.
Dr Alys Havard: firstname.lastname@example.org
Drug use during pregnancy and related harms; use, effectiveness and safety of prescription medicines, including among specific populations such as pregnant women and people with cardiovascular disease; smoking cessation; data linkage
Dr Winifred Asare-Doku: email@example.com
Mental health, behavioural health, dual diagnosis, suicide, alcohol & other drugs among populations such as the criminal justice system, young people, culturally and linguistically diverse people, and low - and middle-income countries. Workplace mental health programs, policy studies, intervention research, and evaluation of programs and services.
Dr Peter Gates: firstname.lastname@example.org
Cannabis use and related harms; Evidence-base treatments for cannabis use disorder; Medicinal cannabis use; Community level drug and alcohol use and related harms: measurement and community-level prevention programs
Dr Duong (Danielle) Tran: Danielle.Tran@unsw.edu.au
Medication use in pregnancy and associated health outcomes for mothers and babies; use of medicines and health services for chronic disease management; evaluation of health intervention program; cross-sectional and longitudinal surveys; health record linkages of electronic medical records, hospital admissions, claims and mortality data.
Dr Simon Clay: email@example.com
Qualitative research; gender diverse populations; substance dependency & health; methamphetamine use; opioid dependency; identity; social theory; drug trends; mental health; feminist & queer theory; public health policy
Dr Rachel Sutherland: firstname.lastname@example.org
Trends in illicit drug use, harms, and market features; implementation, uptake and evaluation of strategies to reduce risk of drug-related harm (e.g., fentanyl test strips, drug alerts); injecting drug use. Projects draw on cross-sectional surveys, longitudinal surveys, and online data (e.g., darknet marketplace listings).
Dr Stella Settumba Stolk: email@example.com
Health Economics: Costs of interventions; Economic evaluations i.e. cost benefit analysis, cost-effectiveness analysis, and cost-utility analysis; valuing the benefits of interventions and policy options using stated preference methods i.e. discrete choice experiments and contingent valuations.
Dr Catherine Foley: firstname.lastname@example.org
Mental health, substance use, psychological trauma, and co-occurring conditions; development of collaborative, pragmatic models of care designed and driven by people who provide and/or receive health services; integration of research into clinical practice in regional, rural, and remote Australia.